When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...

Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes ...

Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities.

The day we discovered that our then 15-month-old baby was one of just 200 people in the world with a genetic brain condition will be for ever etched on my mind.

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating ...

Morgan Stanley Technology, Media & Telecom Conference 2026 March 3, 2026 12:15 PM ESTCompany ParticipantsEric Lefkofsky ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsSean McClain - Founder, CEO, ...

Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive ...

The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took ...

A practical MCP security benchmark for 2026: scoring model, risk map, and a 90-day hardening plan to prevent prompt injection, secret leakage, and permission abuse.

This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.

By David Jeans and Mike Stone NEW YORK, March 4 (Reuters) - Palantir is the latest company to face the painful task of ...